Plain-English translation of NCT05955066 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing baricitinib, a medication called a JAK inhibitor, to see if it can help repair bone damage in people with rheumatoid arthritis. You'll take one pill daily for 6 months, and researchers will use special imaging to measure whether the medication helps bones heal compared to a placebo (inactive pill).
Rheumatoid arthritis can cause permanent damage to bones and joints, leading to pain and loss of function. Currently, preventing further damage is the main goal of treatment—but this medication might actually help repair damage that has already happened, which could be a major step forward.
You likely qualify if…
You likely don't qualify if…
You will take one capsule by mouth every day for 24 weeks (about 6 months)—either the study medication or a placebo, decided by random assignment. You'll visit the clinic at 4 weeks, 12 weeks, and 24 weeks for check-ups to monitor how you're doing and check for any side effects. At the end, special imaging will measure whether your bones have started to heal.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Hong Kong